Key Developments: Horizon Pharma PLC (HZNP.O)

HZNP.O on Nasdaq

17.02USD
12 Feb 2016
Change (% chg)

$0.89 (+5.52%)
Prev Close
$16.13
Open
$16.57
Day's High
$17.10
Day's Low
$15.90
Volume
3,482,509
Avg. Vol
5,954,028
52-wk High
$39.49
52-wk Low
$12.86

Search Stocks

Latest Key Developments (Source: Significant Developments)

Horizon Pharma PLC and Fox Chase Cancer Center Temple Health Initiate Phase 1 Study to Evaluate ACTIMMUNE
Monday, 14 Dec 2015 07:00am EST 

Horizon Pharma PLC:Announced that it, in collaboration with Fox Chase Cancer Center Temple Health, has initiated a Phase 1 clinical study to evaluate ACTIMMUNE (interferon gamma-1b) in combination with nivolumab in advanced solid tumors.  Full Article

Horizon Pharma PLC to acquire Crealta Holdings LLC in all cash acquisition
Friday, 11 Dec 2015 07:00am EST 

Horizon Pharma PLC:Announced it has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.  Full Article

Horizon Pharma plc Receives European Commission Approval for RAVICTI Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Two Months of Age and Older
Monday, 30 Nov 2015 07:00am EST 

Horizon Pharma PLC:Says European Commission (EC) has adopted a binding decision to approve RAVICTI (glycerol phenylbutyrate) Oral Liquid for use as an adjunctive therapy for chronic management of adult and pediatric patients two months of age and older with six subtypes of Urea Cycle Disorders (UCDs).  Full Article

Horizon Pharma PLC announces collaboration with Alliance for Lupus Research
Wednesday, 11 Nov 2015 07:00am EST 

Horizon Pharma PLC:Announces collaboration with alliance for lupus research to study Rayos(R) (prednisone) delayed-release tablets in systemic lupus erythematosus.First study undercollaboration will investigate effect of rayos on fatigue experienced by lupus erythematosus patients.  Full Article

Horizon Pharma PLC gives FY 2016 guidance and FY 2020 sales guidance
Monday, 9 Nov 2015 07:00am EST 

Horizon Pharma PLC:Sees FY 2016 net sales guidance of $950 million to $975 million.Sees FY 2016 adjusted EBITDA guidance of $460 million to $475 million.Sees FY 2020 long-range plan net sales estimated to exceed $2 billion.  Full Article

Horizon Pharma extends offer to acquire Depomed Inc,
Monday, 26 Oct 2015 05:42pm EDT 

Horizon Pharma PLC:Extends offer to acquire Depomed Inc.Extended expiration of exchange offer to acquire shares of Depomed to 5 p.m., eastern time, on November 20, 2015.Says exchange offer was previously scheduled to expire at 5 p.m., eastern time on November 6, 2015.Says all other terms and conditions of the exchange offer remain unchanged.  Full Article

Horizon Pharma PLC announces favorable markman ruling in RAVICTI oral liquid patent infringement lawsuit
Wednesday, 21 Oct 2015 07:00am EDT 

Horizon Pharma PLC:Announces favorable markman ruling in RAVICTI oral liquid patent infringement lawsuit.Says favorable markman ruling has been issued in patent infringement lawsuit filed by horizon against par pharmaceutical.Patent infringement lawsuit was filed by horizon for abbreviated new drug application to market a generic version of RAVICTI.  Full Article

Depomed Inc's board of directors rejects Horizon Pharma plc's unsolicited exchange offer
Monday, 14 Sep 2015 08:00am EDT 

Depomed Inc:Says board of directors unanimously concluded that Horizon Pharma plc's unsolicited exchange offer significantly undervalues Depomed.Says board urges shareholders not to exchange shares as offer significantly undervalues Depomed.  Full Article

Horizon Pharma PLC commences exchange offer to acquire all Depomed Inc, common shares
Tuesday, 8 Sep 2015 07:00am EDT 

Horizon Pharma PLC:Commences exchange offer to acquire all Depomed Inc, common shares.Tendering Depomed shareholders would be able to exchange each share of Depomed common stock for 0.95 Horizon Pharma ordinary shares.Depomed shareholders to have a pro forma ownership of approximately 32 percent of combined company.Sees combined co pro forma 2015 estimated net sales of approximately $1 billion and adjusted EBITDA of approximately $375 million.Says offer is scheduled to expire at 5 p.m., eastern time, on November 6, 2015.Says in addition to exchange offer, Horizon Pharma also filed solicitation statement with SEC to be delivered to Depomed shareholders.  Full Article

Horizon Pharma PLC reaffirms FY 2015 guidance
Friday, 7 Aug 2015 07:00am EDT 

Horizon Pharma PLC:Sees FY 2015 net sales of between $660 to $680 million.Sees FY 2015 Adjusted EBITDA of between $265 to $280 million.  Full Article

Horizon Pharma acquires Crealta Holdings for $510 million

Specialty drug maker Horizon Pharma said on Friday it has agreed to buy Crealta Holdings for $510 million in cash, adding the only U.S.-approved treatment for a type of arthritis to its portfolio.

Search Stocks